Filtered By:
Condition: Heart Attack
Therapy: Dialysis
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 432 results found since Jan 2013.
Retrograde chronic total occlusion percutaneous coronary intervention using single catheter: A single centre registry
CONCLUSIONS: Retrograde CTO PCI using single catheter is a technically challenging procedure when compared with other CTO PCI. Our study demonstrated acceptable outcomes which is comparable to other antegrade and retrograde CTO PCI registries.PMID:34474754 | PMC:PMC8424288 | DOI:10.1016/j.ihj.2021.06.006
Source: Indian Heart J - September 3, 2021 Category: Cardiology Authors: Prathap Kumar Blessvin Jino Ali Shafeeq Stalin Roy Manu Rajendran Sandheep George Villoth Source Type: research
Short- and long-term outcome of patients with spontaneous echo contrast or thrombus in the left atrial appendage in the era of the direct acting anticoagulants
ConclusionEven in the DOAC era, the occurrence of thrombus or SEC in the LAA is associated with a high rate of MACCE. Our study suggests that the choice of DOAC therapy may have an impact on long-term survival.Graphic abstract
Source: Clinical Research in Cardiology - August 26, 2021 Category: Cardiology Source Type: research
Major Adverse Renal and Cardiovascular Events following Intra-Arterial Contrast Media Administration in Hospitalized Patients with Comorbid Conditions
Conclusion: Intra-arterial administration using IOCM in at-risk patients is associated with lower rates of MARCE than the use of LOCM. This difference is especially apparent in patients with a combination of CKD 3 –4 and diabetes and in patients with CTO, providing real-world data validation with meaningful NNT in favor of IOCM.Cardiorenal Med
Source: Cardiorenal Medicine - August 12, 2021 Category: Urology & Nephrology Source Type: research
Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials
CONCLUSIONS: Roxadustat was more effective than placebo at increasing hemoglobin in patients with non-dialysis-dependent CKD and anemia, while decreasing transfusion rate and being noninferior to placebo with respect to risk of MACE.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis, NCT01750190; Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis (ALPS), NCT01887600; Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not ...
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 7, 2021 Category: Urology & Nephrology Authors: Robert Provenzano Lynda Szczech Robert Leong Khalil G Saikali Ming Zhong Tyson T Lee Dustin J Little Mark T Houser Lars Frison John Houghton Thomas B Neff Source Type: research
